Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio-Techne (TECH) EBT (2016 - 2026)

Bio-Techne has reported EBT over the past 17 years, most recently at $50.8 million for Q4 2025.

  • For Q4 2025, EBT rose 18.44% year-over-year to $50.8 million; the TTM value through Dec 2025 reached $27.4 million, down 84.35%, while the annual FY2025 figure was $11.6 million, 93.34% down from the prior year.
  • EBT for Q4 2025 was $50.8 million at Bio-Techne, up from $48.0 million in the prior quarter.
  • Over five years, EBT peaked at $103.7 million in Q3 2022 and troughed at -$176.1 million in Q2 2022.
  • A 5-year average of $33.5 million and a median of $48.8 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: soared 150.16% in 2023 and later crashed 456.34% in 2025.
  • Year by year, EBT stood at $86.2 million in 2021, then fell by 22.92% to $66.4 million in 2022, then crashed by 49.74% to $33.4 million in 2023, then rose by 28.42% to $42.9 million in 2024, then increased by 18.44% to $50.8 million in 2025.
  • Business Quant data shows EBT for TECH at $50.8 million in Q4 2025, $48.0 million in Q3 2025, and -$109.7 million in Q2 2025.